



Huddinge  
12 November 2002

## **Tripep reinforces patent portfolio**

Tripep has been granted two new US patents, one for its HIV-inhibitory peptides and one for its RAS platform technology.

Tripep's RAS platform technology forms the basis, among other things, for the company's development of drugs that target staphylococcus aureus (the bacteria that cause nosocomial, or hospital-acquired, infections). The RAS technology (where RAS stands for Redirecting Antibody Specificity) involves redirecting existing antibodies so that they will attack and eliminate a different infectious agent.

The new patents have further reinforced Tripep's existing patent portfolio.

In addition, two patent applications for the ChronVac-C vaccine have been made public in the US, thus enhancing this product's protection.

*For more information, please contact Anders Vahlne, Head of Research,  
Tel.: +46 8 5858 1313 or mobile +46 709 28 05 28,  
e-mail: anders.vahlne@tripep.se*